Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome

Patient Selection and Clinical Outcomes in the STOPDAPT-2 Trial

(2021) Kenji Kanenawa et al.   Circulation-Cardiovascular Interventions

Management of Antithrombotic Therapy after Acute Coronary Syndromes

(2021) Fatima Rodriguez et al.   NEW ENGLAND JOURNAL OF MEDICINE

P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials

(2021) Marco Valgimigli et al.   BMJ-British Medical Journal

JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease

(2020) Masato Nakamura et al.   CIRCULATION JOURNAL

Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome

(2020) Byeong-Keuk Kim et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

(2020) Jean-Philippe Collet et al.   EUROPEAN HEART JOURNAL

Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS

(2020) Usman Baber et al.   EUROPEAN HEART JOURNAL

Application of the Modified High Bleeding Risk Criteria for Japanese Patients in an All-Comers Registry of Percutaneous Coronary Intervention　― From the CREDO-Kyoto Registry Cohort-3 ―

(2020) Masahiro Natsuaki et al.   CIRCULATION JOURNAL

Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials

(2020) Daniele Giacoppo et al.   EUROPEAN HEART JOURNAL

Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention

(2019) Philip Urban et al.   CIRCULATION

Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention

(2019) Joo-Yong Hahn et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI

(2019) Hirotoshi Watanabe et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Ticagrelor with or without Aspirin in High-Risk Patients after PCI

(2019) Roxana Mehran et al.   NEW ENGLAND JOURNAL OF MEDICINE

Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes

(2019) Mariusz Tomaniak et al.   JAMA Cardiology

Application of the Academic Research Consortium High Bleeding Risk Criteria in an All-Comers Registry of Percutaneous Coronary Intervention

(2019) Masahiro Natsuaki et al.   Circulation-Cardiovascular Interventions

Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO‐Kyoto Thrombotic and Bleeding Risk Scores

(2018) Masahiro Natsuaki et al.   Journal of the American Heart Association

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

(2018) Pascal Vranckx et al.   LANCET

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS

(2017) Marco Valgimigli et al.   EUROPEAN HEART JOURNAL

2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery

(2016) Glenn N. Levine et al.   CIRCULATION

Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents

(2016) Usman Baber et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent

(2013) Masahiro Natsuaki et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting

(2012) Marco Valgimigli et al.   CIRCULATION

Comparison of Everolimus-Eluting and Sirolimus-Eluting Coronary Stents

(2012) Takeshi Kimura et al.   CIRCULATION

Third Universal Definition of Myocardial Infarction

(2012) Kristian Thygesen et al.   CIRCULATION

A New Strategy for Discontinuation of Dual Antiplatelet Therapy

(2012) Byeong-Keuk Kim et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Randomized Trial of Stents versus Bypass Surgery for Left Main Coronary Artery Disease

(2011) Seung-Jung Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

(2009) Lars Wallentin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease

(2009) Patrick W. Serruys et al.   NEW ENGLAND JOURNAL OF MEDICINE